PMID- 34461859
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20211018
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Aug 30
TI  - Infiltration of CD1a-positive dendritic cells in advanced laryngeal cancer 
      correlates with unfavorable outcomes post-laryngectomy.
PG  - 973
LID - 10.1186/s12885-021-08715-6 [doi]
LID - 973
AB  - BACKGROUND: The prognosis of advanced laryngeal cancer is unfavorable despite 
      advances in multidisciplinary therapy. Dendritic cells (DCs) play a central role 
      in antitumor immunity. Tumor-infiltrating CD1a(+) DCs have been reported to be 
      associated with clinical outcomes in carcinomas of various organs, but the 
      clinical impact of CD1a(+) DCs in laryngeal cancer remains to be unequivocally 
      established. METHODS: We retrospectively analyzed the cases of 57 patients with 
      Stage III or IV laryngeal cancer who underwent a total laryngectomy. 
      Immunohistochemistry detection of CD1a, S100 and CD8 was performed on 
      representative resected specimens. CD1a(+) DCs, S100(+) DCs and CD8(+) cytotoxic 
      T-lymphocytes (CTLs) were evaluated, and the cases divided into high and low 
      groups according to the cut-off of the median values for each of these 3 
      parameters. RESULTS: Compared to the CD1a-low group, the CD1a-high group had more 
      advanced cases and showed significantly worse disease-specific survival (DSS) 
      (P = 0.008) and overall survival (OS) (P = 0.032). The analyses of S100 DCs and 
      CD8(+) CTLs revealed no significant impact on clinical outcomes. However, 
      multivariate analysis revealed that infiltration of CD1a(+) DCs was an 
      independent unfavorable prognostic factor for both DSS (P = 0.009) and OS 
      (P = 0.013). CONCLUSIONS: Our results demonstrated that the infiltration of 
      CD1a(+) DCs was associated with unfavorable clinical outcomes in patients with 
      advanced laryngeal cancer who underwent a total laryngectomy as the initial 
      treatment.
CI  - (c) 2021. The Author(s).
FAU - Minesaki, Akimichi
AU  - Minesaki A
AD  - Department of Pathology & Microbiology, Saga University Faculty of Medicine, 
      Saga, Japan.
AD  - Department of Otolaryngology - Head & Neck Surgery, Saga University Faculty of 
      Medicine, Saga, Japan.
FAU - Kai, Keita
AU  - Kai K
AUID- ORCID: 0000-0003-1553-2598
AD  - Department of Pathology, Saga University Hospital, Nabeshima 5-1-1, Saga City, 
      Saga, 849-8501, Japan. kaikeit@cc.saga-u.ac.jp.
FAU - Kuratomi, Yuichiro
AU  - Kuratomi Y
AD  - Department of Otolaryngology - Head & Neck Surgery, Saga University Faculty of 
      Medicine, Saga, Japan.
FAU - Aishima, Shinichi
AU  - Aishima S
AD  - Department of Pathology & Microbiology, Saga University Faculty of Medicine, 
      Saga, Japan.
AD  - Department of Pathology, Saga University Hospital, Nabeshima 5-1-1, Saga City, 
      Saga, 849-8501, Japan.
LA  - eng
GR  - JP20K07408/Japan Society for the Promotion of Science/
PT  - Journal Article
DEP - 20210830
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Antigens, CD1)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD1a antigen)
SB  - IM
MH  - Aged
MH  - Antigens, CD1/*metabolism
MH  - Biomarkers, Tumor/*analysis
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Laryngeal Neoplasms/immunology/*mortality/pathology/surgery
MH  - Laryngectomy/*mortality
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Male
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
PMC - PMC8406956
OTO - NOTNLM
OT  - CD1a
OT  - Dendritic cell
OT  - Immunohistochemistry
OT  - Laryngeal cancer
OT  - Prognosis
COIS- The authors have no conflicts of interest to declare.
EDAT- 2021/09/01 06:00
MHDA- 2021/10/21 06:00
PMCR- 2021/08/30
CRDT- 2021/08/31 05:36
PHST- 2020/08/17 00:00 [received]
PHST- 2021/08/23 00:00 [accepted]
PHST- 2021/08/31 05:36 [entrez]
PHST- 2021/09/01 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2021/08/30 00:00 [pmc-release]
AID - 10.1186/s12885-021-08715-6 [pii]
AID - 8715 [pii]
AID - 10.1186/s12885-021-08715-6 [doi]
PST - epublish
SO  - BMC Cancer. 2021 Aug 30;21(1):973. doi: 10.1186/s12885-021-08715-6.